<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Gakiopoulou, H</style></author><author><style face="normal" font="default" size="100%">P Korkolopoulou</style></author><author><style face="normal" font="default" size="100%">G Levidou</style></author><author><style face="normal" font="default" size="100%">Thymara, I.</style></author><author><style face="normal" font="default" size="100%">Saetta, A.</style></author><author><style face="normal" font="default" size="100%">Piperi, C.</style></author><author><style face="normal" font="default" size="100%">Givalos, N.</style></author><author><style face="normal" font="default" size="100%">Vassilopoulos, I.</style></author><author><style face="normal" font="default" size="100%">Ventouri, K.</style></author><author><style face="normal" font="default" size="100%">Tsenga, A.</style></author><author><style face="normal" font="default" size="100%">Bamias, A.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.-A.</style></author><author><style face="normal" font="default" size="100%">Agapitos, E.</style></author><author><style face="normal" font="default" size="100%">Patsouris, E.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Minichromosome maintenance proteins 2 and 5 in non-benign epithelial ovarian tumours: Relationship with cell cycle regulators and prognostic implications</style></title><secondary-title><style face="normal" font="default" size="100%">British Journal of Cancer</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Ki-67</style></keyword><keyword><style  face="normal" font="default" size="100%">MCM-2</style></keyword><keyword><style  face="normal" font="default" size="100%">MCM-5</style></keyword><keyword><style  face="normal" font="default" size="100%">Ovarian adenocarcinomas</style></keyword><keyword><style  face="normal" font="default" size="100%">Ovarian low malignant potential tumours</style></keyword><keyword><style  face="normal" font="default" size="100%">Survival</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2007</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-35348830387&amp;doi=10.1038%2fsj.bjc.6603992&amp;partnerID=40&amp;md5=a33b3b682ed4507dcde1915723b08259</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">97</style></volume><pages><style face="normal" font="default" size="100%">1124 - 1134</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Minichromosome maintenance proteins (MCM) have recently emerged as novel proliferation markers with prognostic implications in several tumour types. This is the first study investigating MCM-2 and MCM-5 immunohistochemical expression in a series of ovarian adenocarcinomas and low malignant potential (LMP) tumours aiming to determine possible associations with clinicopathological parameters, the conventional proliferation index Ki-67, cell cycle regulators (p53, p27Kip1, p21WAF1 and pRb) and patients' outcome. Immunohistochemistry was applied in a series of 43 cases of ovarian LMP tumours and 85 cases of adenocarcinomas. Survival analysis was restricted to adenocarcinomas. The median MCM-2 and MCM-5 labelling indices (LIs) were significantly higher in adenocarcinomas compared to LMP tumours (P&amp;lt;0.0001 for both associations). In adenocarcinomas, the levels of MCM-2 and MCM-5 increased significantly with advancing tumour stage (P=0.0052 and P=0.0180, respectively), whereas both MCM-2 and MCM-5 increased significantly with increasing tumour grade (P=0.0002 and P=0.0006, respectively) and the presence of bulky residual disease (P&amp;lt;0.0001 in both relationships). A strong positive correlation was established between MCM-2 or MCM-5 expression level and Ki-67 LI (P&amp;lt;0.0001) as well as p53 protein (P=0.0038 and P=0.0500, respectively). Moreover, MCM-2 LI was inversely correlated with p27Kip-1 LI (P=0.0068). Finally, both MCM-2 and MCM-5 were associated significantly with adverse patients' outcome in both univariate (≥20 vs &amp;gt;20%, P=0.0011 and ≥25 vs &amp;lt;25%, P=0.0100, respectively) and multivariate (P=0.0001 and 0.0090, respectively) analysis. An adequately powered independent group of 45 patients was used in order to validate our results in univariate survival analysis. In this group, MCM-2 and MCM-5 expression retained their prognostic significance (P&amp;lt;0.0001 in both relationships). In conclusion, MCM-2 and MCM-5 proteins appear to be promising as prognostic markers in patients with ovarian adenocarcinomas. © 2007 Cancer Research UK.</style></abstract><issue><style face="normal" font="default" size="100%">8</style></issue><notes><style face="normal" font="default" size="100%">Cited By :23Export Date: 21 February 2017</style></notes></record></records></xml>